Taylor & Francis Group
Browse
kadi_a_1516098_sm1674.pptx (658.51 kB)

SGLT6 - A pharmacological target for the treatment of obesity?

Download (658.51 kB)
presentation
posted on 2018-11-07, 22:31 authored by Tamara Baader-Pagler, Matthias Eckhardt, Frank Himmelsbach, Achim Sauer, Birgit E. Stierstorfer, Bradford S. Hamilton

Despite increased knowledge of nutrient intake regulation and energy homeostasis, treatment options for obesity remain limited. Food reward consists of two branches: gustatory and post-ingestive nutritive information. Drosophila lacking dSLC5A11 (sodium/glucose cotransporter 6-SGLT6) prefer L-glucose over D-glucose independently of their state of satiety. Human SGLT6 is an active transporter of myo-inositol and D-glucose. We investigated expression of SGLT6 in human tissue and found a significant expression in the small intestine and brain. The preference between a metabolizable and a non-metabolizable sugar was tested in 3 mouse models with a selective and potent SGLT6 inhibitor. No influence on sugar preference was seen with SGLT6 inhibition. These studies suggest that SGLT6 does not play a significant role in nutrient sensing in mammals.

History